{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T04:19:43Z","timestamp":1743481183902},"reference-count":45,"publisher":"Japan Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej13-0198","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T23:32:56Z","timestamp":1375486376000},"page":"1207-1214","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy"],"prefix":"10.1507","volume":"60","author":[{"given":"Seiya","family":"Shimoda","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iwashita","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ichimori","sequence":"additional","affiliation":[{"name":"Ueki Hospital, Kumamoto 861-0136, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Saiseikai Kumamoto Hospital, Kumamoto 861-4193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Sekigami","sequence":"additional","affiliation":[{"name":"Kumamoto Social Insurance General Hospital, Yatsushiro 866-0856, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Motoshima","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Minamata City Hospital and Medical Center, Minamata 867-0041, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Donner T, Mu&ntilde;oz M (2012) Update on insulin therapy for type 2 diabetes. <i>J Clin Endocrinol Metab<\/i> 97: 1405-1413.","DOI":"10.1210\/jc.2011-2202"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Testa MA, Gill J, Su M, Turner RR, Blonde L, <i>et al<\/i>. (2012) Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. <i>J Clin Endocrinol Metab<\/i> 97: 3504-3514.","DOI":"10.1210\/jc.2012-1763"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fritsche A, Larbig M, Owens D, H&auml;ring HU; GINGER study group (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. <i>Diabetes Obes Metab<\/i> 12: 115-123.","DOI":"10.1111\/j.1463-1326.2009.01165.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, <i>et al<\/i>. (2011) Efficacy of insulin analogs in achieving the hemoglobin A1c target of &lt;7% in type 2 diabetes: meta-analysis of randomized controlled trials. <i>Diabetes Care<\/i> 34: 510-517.","DOI":"10.2337\/dc10-1710"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, <i>et al<\/i>. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. <i>Diabetes Res Clin Pract<\/i> 28: 103-117.","DOI":"10.1016\/0168-8227(95)01064-K"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, <i>et al<\/i>. (2000) Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. <i>Diabetes Res Clin Pract<\/i> 48: 201-210.","DOI":"10.1016\/S0168-8227(00)00122-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, <i>et al<\/i>. (2008) Effects of intensive glucose lowering in type 2 diabetes. <i>N Engl J Med<\/i> 358: 2545-2559.","DOI":"10.1056\/NEJMoa0802743"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, <i>et al<\/i>. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>N Engl J Med<\/i> 358: 2560-2572.","DOI":"10.1056\/NEJMoa0802987"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, <i>et al<\/i>.; VADT Investigators. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. <i>N Engl J Med<\/i> 360: 129-139.","DOI":"10.1056\/NEJMoa0808431"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Davies M, Sinnassamy P, Storms F, Gomis R; AT.LANTUS Study Group (2008) Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. <i>Diabetes Res Clin Pract<\/i> 79: 368-375.","DOI":"10.1016\/j.diabres.2007.09.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K (2011) Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. <i>Endocr Pract<\/i> 17: 727-736.","DOI":"10.4158\/EP10367.OR"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abrahamson MJ, Peters A (2012) Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy. <i>Ann Med<\/i> 44: 836-846.","DOI":"10.3109\/07853890.2012.699715"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG (2012) Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. <i>Diabetes Care<\/i> 35: 495-497.","DOI":"10.2337\/dc11-1171"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes Obes Metab<\/i> 9: 194-205.","DOI":"10.1111\/j.1463-1326.2006.00704.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, <i>et al<\/i>. (2008) Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. <i>Diabetes Res Clin Pract<\/i> 79: 291-298.","DOI":"10.1016\/j.diabres.2007.08.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. <i>Diabetes Care<\/i> 29: 2638-2643.","DOI":"10.2337\/dc06-0706"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, <i>et al<\/i>.; Sitagliptin Study 035 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. <i>Diabetes Obes Metab<\/i> 9: 733-745.","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Clin Ther<\/i> 28: 1556-1568.","DOI":"10.1016\/j.clinthera.2006.10.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, <i>et al<\/i>. (2011) Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. <i>Diabetol Int<\/i> 2: 32-44.","DOI":"10.1007\/s13340-011-0022-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, <i>et al<\/i>. (2007) Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. <i>Diabetologia<\/i> 50: 1148-1155.","DOI":"10.1007\/s00125-007-0633-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, <i>et al<\/i>. (2009) Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. <i>Diabetes Obes Metab<\/i> 11: 1145-1152.","DOI":"10.1111\/j.1463-1326.2009.01124.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Vilsb&oslash;ll T, Rosenstock J, Yki-J&auml;rvinen H, Cefalu WT, Chen Y, <i>et al<\/i>. (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 12: 167-177.","DOI":"10.1111\/j.1463-1326.2009.01173.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, <i>et al<\/i>. (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. <i>Diabetes Care<\/i> 33: 1509-1515.","DOI":"10.2337\/dc09-2191"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, <i>et al<\/i>. (2012) Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. <i>Endocr J <\/i>59: 1131-1136.","DOI":"10.1507\/endocrj.EJ12-0220"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, <i>et al<\/i>. (2012) Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. <i>Diabetes Obes Metab<\/i> 14: 795-802.","DOI":"10.1111\/j.1463-1326.2012.01600.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K (2013) Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. <i>Diabetes Technol Ther<\/i> 15: 237-240.","DOI":"10.1089\/dia.2012.0214"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M (2013) Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. <i>Endocr J<\/i> 60: 733-742.","DOI":"10.1507\/endocrj.EJ12-0293"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Schlichtkrull J, Munck O, Jersild M (1965) The M-value, an index of blood-sugar control in diabetics. <i>Acta Med Scand<\/i> 77: 95-102.","DOI":"10.1111\/j.0954-6820.1965.tb01810.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, <i>et al<\/i>. (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. <i>Diabetes<\/i> 19: 644-655.","DOI":"10.2337\/diab.19.9.644"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, <i>et al<\/i>. (2007) Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. <i>Diabetologia<\/i> 50: 1148-1155.","DOI":"10.1007\/s00125-007-0633-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Fravel MA, McDanel DL, Ross MB, Moores KG, Starry MJ (2011) Special considerations for treatment of type 2 diabetes mellitus in the elderly. <i>Am J Health Syst Pharm<\/i> 68: 500-509.","DOI":"10.2146\/ajhp080085"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Park H, Park C, Kim Y, Rascati KL (2012) Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. <i>Ann Pharmacother<\/i> 46: 1453-69.","DOI":"10.1345\/aph.1R041"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, <i>et al<\/i>. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. <i>Diabetologia<\/i> 56: 696-708.","DOI":"10.1007\/s00125-012-2827-3"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, <i>et al<\/i>. (2011) Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. <i>Diabetes Care<\/i> 34: 1164-1170.","DOI":"10.2337\/dc10-1915"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Monnier L, Mas E, Ginet C, Michel F, Villon L, <i>et al<\/i>. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. <i>JAMA<\/i> 295: 1681-1687.","DOI":"10.1001\/jama.295.14.1681"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Brownlee M, Hirsch IB (2006) Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. <i>JAMA<\/i> 295: 1707-1708.","DOI":"10.1001\/jama.295.14.1707"},{"key":"37","unstructured":"37. Meneilly GS, Tessier D (2001) Diabetes in elderly adults. <i>J Gerontol A Biol Sci Med Sci<\/i> 56: M5-13."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Pi-Sunyer FX (2008) The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. <i>Postgrad Med<\/i> 120: 5-17.","DOI":"10.3810\/pgm.2008.07.1785"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. <i>JAMA<\/i> 287: 360-372.","DOI":"10.1001\/jama.287.3.360"},{"key":"40","unstructured":"40. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, <i>et al<\/i>. (2011) Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. <i>Diabetes Res Clin Pract<\/i> 95: e27-e28."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, <i>et al<\/i>. (2012) Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. <i>J Diabetes Invest<\/i> 3: 503-509.","DOI":"10.1111\/j.2040-1124.2012.00221.x"},{"key":"42","unstructured":"42. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, <i>et al<\/i>.; ASSET-K Study Group (2013) Long-term&nbsp;efficacy&nbsp;and safety of&nbsp;sitagliptin&nbsp;in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c &lt;7%. <i>J Endocrinol Invest<\/i> [Epub ahead of print]"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. <i>Diabetes Care<\/i> 35: 2076-2082.","DOI":"10.2337\/dc12-0199"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, <i>et al<\/i>. (1998) Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. <i>Lancet<\/i> 352: 1012-1015.","DOI":"10.1016\/S0140-6736(98)04055-0"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, <i>et al<\/i>. (2003) Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. <i>Diabetes<\/i> 52: 1738-1748.","DOI":"10.2337\/diabetes.52.7.1738"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/10\/60_EJ13-0198\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:39:19Z","timestamp":1618295959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/10\/60_EJ13-0198\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0198","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}